Eluxadoline Drug Asset Due Diligence Report 2026

This Eluxadoline Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Eluxadoline can convert its Small molecule drug profile and δ opioid receptor x κ opioid receptor x μ opioid receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Eluxadoline (query alias: eluxadoline)
Modality / target	Small molecule drug; δ opioid receptor x κ opioid receptor x μ opioid receptor; δ opioid receptor antagonists, κ opioid receptor agonists, μ opioid receptor agonists
Highest global status	Approved
Originator	Actavis
Active developers	AbbVie, Inc., Allergan Pharma Co., Allergan, Inc. (Canada)

The MCP disease footprint includes Irritable bowel syndrome with diarrhea, Irritable Bowel Syndrome, Diarrhea. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03441581	Phase 4	Completed	24	Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period
NCT04880876	Phase 3	Enrolling by invitation	124	Percentage of Participants with Adverse Events
NCT04313088	Phase 2/3	Withdrawn	Not disclosed	Proportion of days with improved bowel movements

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)

Phase 4; n=24; evaluation: not stated. Reported fields: Baseline(Mean) = 5.89 score on a scale (Standard Deviation, 0.639); -; -

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea

Phase 2; n=807; evaluation: not stated. Reported fields: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4 = 5.7 percentage of participants ; Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4: Odds Ratio (OR) = 2.457(95% CI, 0.994 - 6.077), P-Value = 0.052; Odds Ratio (OR) = 2.383(95% CI, 1.036 - 5.478), P-Value = 0.041; Odds Ratio (OR) = 2.079(95% CI, 0.893 - 4.842), P-Value = 0.090; Odds Ratio (OR) = 2.797(95% CI, 1.227 - 6.376), P-Value = 0.015; Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4 = 11.0 percentage of participants

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study

Phase 4; n=346; evaluation: Positive. Reported fields: Primary composite responder endpoint(≥40% WAP improvement and <5 Bristol Stool Scale score) = 10.3 % ; Primary composite responder endpoint(≥40% WAP improvement and <5 Bristol Stool Scale score) = 22.7 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Eluxadoline addresses Irritable bowel syndrome with diarrhea, Irritable Bowel Syndrome, Diarrhea. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2014-04-28	Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI)	Not disclosed	US$1,100.0M stated total
2009-11-01	Furiex Pharmaceuticals licensed A fluoroquinolone antibiotic compound from Janssen Pharmaceutica	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Composition of opioid receptor modulator and MDMA for use thereof”. The milestone feed surfaced a patent-application signal described as “Development of chromatographic method for estimation of eluxadoline in synthetic mixture”. The milestone feed surfaced a patent-application signal described as “Validation of chromatographic method for estimation of eluxadoline in synthetic mixture”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO